COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES

Disclosed are combination therapies comprising administration of a CD73 inhibitor, an adenosine A2A or A2B receptor inhibitor, and a PD-1/PD-L1 inhibitor. The disclosed combination therapies are useful in the treatment of diseases related to the activity of adenosine receptors and/or CD73 and/or PD-1/PD-L1 including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases. Anti-CD73 antibodies, PD-1/PD-L1 inhibitors, and A2A/A2B inhibitors are also disclosed. Se describen terapias combinadas que comprenden la administración de un inhibidor de CD73, un inhibidor de los receptores de adenosina A2A o A2B y un inhibidor de PD-1/PD-L1. Las terapias combinadas descritas son útiles en el tratamiento de enfermedades relacionadas con la actividad de los receptores de adenosina y/o CD73 y/o PD-1/PD-L1 incluidas, por ejemplo, cáncer, enfermedades inflamatorias, enfermedades cardiovasculares y enfermedades neurodegenerativas. También se describen anticuerpos anti-CD73, inhibidores de PD-1/PD-L1 e inhibidores de A2A/A2B.